Decoy Therapeutics Announces 1-for-12 Split, Cutting Shares to 532K
Decoy Therapeutics will implement a 1-for-12 reverse stock split at 5 p.m. ET on March 6, reducing shares outstanding from about 6.38 million to roughly 532,000. The split is designed to meet Nasdaq’s $1.00 minimum bid requirement and will proportionally adjust all options, warrants and equity incentive plan reserves.
1. Reverse Split Implementation
Decoy Therapeutics will effect a 1-for-12 reverse stock split at 5 p.m. ET on March 6, 2026, with split-adjusted trading beginning March 9 under CUSIP 79400X602. The split will reduce its common shares outstanding from approximately 6.38 million to about 532,000.
2. Nasdaq Compliance Objective
The reverse split is intended to restore compliance with Nasdaq Capital Market’s requirement of a $1.00 minimum closing bid price for continued listing. The board selected the 1-for-12 ratio following stockholder approval of a ratio range from 1-for-4 to 1-for-15 at a February 24 meeting.
3. Adjustments to Securities and Shareholders
All outstanding options, warrants and shares reserved under the 2015 Equity Incentive Plan and Employee Stock Purchase Plan will be proportionally adjusted. Fractional shares will be paid in cash based on the March 6 closing price, and Equiniti Trust will act as exchange agent and transfer agent.